Delving into the Latest Updates on Cytocraft Biopharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Digestive System Disorders

Biological products

Autologous CAR-T

TCR-T Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5

Top 5 Drug Type	Count

Biological products	1
Autologous CAR-T	1
TCR-T Cell therapy	1
Immune cell therapy	1
Fusion protein	1

Top 5 Target	Count

CD276(CD276 antigen)	2
BRMS1L x IL-23 x V-set domain containing	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

IND Approval

Phase 1

3

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.)	Solid tumor More	Phase 1
SDTM001 ( CD276 )	Non-Small Cell Lung Cancer More	Phase 1
Anti-B7-H3 CAR-T (Cytocraft Biopharmaceutical ) ( CD276 )	Colorectal Cancer More	Phase 1
CAPRI(cytocraft)	stage IIA non-small cell lung cancer More	Clinical
SDT-T002	Advanced Hepatocellular Carcinoma More	IND Approval